Expression of p38MAPK in the hippocampal CA1 region of rats with Abeta25-35-induced Alzheimer disease.
- Author:
Gui-lian ZHANG
1
;
Li YAO
;
Yun DU
;
Ru ZHANG
;
Ning BU
;
Jing-jie LIU
;
Hai-feng YUAN
;
Hai-qin WU
Author Information
- Publication Type:Journal Article
- MeSH: Alzheimer Disease; chemically induced; enzymology; metabolism; Amyloid beta-Peptides; administration & dosage; toxicity; Animals; Hippocampus; drug effects; enzymology; Immunohistochemistry; Male; Maze Learning; drug effects; Peptide Fragments; administration & dosage; toxicity; Random Allocation; Rats; Rats, Sprague-Dawley; p38 Mitogen-Activated Protein Kinases; biosynthesis
- From: Journal of Southern Medical University 2008;28(7):1176-1179
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the changes of p38MAPK expression in a rat model of Alzheimer disease (AD).
METHODSSeventy-two adult SD rats were randomized equally into 4 groups, and a single-dose injection of Abeta25-35 (dementia group), normal saline (saline group), SB203580 (inhibitor group), or DMSO (inhibitor control group) was administered into the lateral cerebral ventricle. Y-maze tast was performed to evaluate the behavioral changes of the rats after the injections, and on days 4, 7 and 14 after the injection, p38MAPK expression in the hippocampal CA1 area was measured by means of immunohistochemistry.
RESULTSOn days 7 and 14 following Abeta25-35 injection, the training times, error number and total reaction time were significantly higher in dementia group than in saline group (P<0.05), but all these indices were significantly lowered in the inhibitor group as compared with the dementia group (P<0.05). Immunohistochemistry revealed obvious p38 expression in the dementia group 4 days after Abeta25-35 injection, which increased significantly with the passage of time (P<0.01). The gray scale in the inhibitor group was significantly higher than that in the dementia group (P<0.01).
CONCLUSIONp38MAPK activation in the hippocampal CA1 area is an event that persists during the entire course of Abeta25-35-induced AD in rats, and the inhibitor SB203580 prevents p38MAPK expression and improves the learning and memory abilities of the rats.
